educational credit
Accreditation
The American College of Medical Genetics is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation
The American College of Medical Genetics and Genomics designates this enduring activity for a maximum of 66 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CE (Continuing Education for non-physicians): This activity has been approved for CE credits.
*The certificate is accepted by the ABMGG for certification.
Genetic Counselor Credit
The National Society of Genetic Counselors (NSGC) has authorized ACMG to offer up to 6.6 CEUs or 66 Category 1 contact hours for the activity ACMG 2020 Digital Edition. The American Board of Genetic Counseling (ABGC) will accept CEUs earned at this program for the purposes of genetic counselor certification and recertification.
ACMG will report completed accredited sessions to NSGC for credit certificates on December 4, 2020, December 3, 2021 and July 8, 2022. Submissions outside of these parameters may incur a processing fee of $40.
P.A.C.E.® CEUs- Laboratory Directors and Laboratory Personnel
ACMG is approved as a provider of continuing education programs in the clinical laboratory sciences by the American Society for Clinical Laboratory Science (ASCLS) Professional Acknowledgment for Continuing Education (P.A.C.E.®) Program. The American College of Medical Genetics and Genomics designates this OnDemand course for a maximum of 66 contact hours. ACMG is approved by the Florida Board of Clinical Laboratory Personnel as CE Provider #50-11878. This course is registered # 20-775394 with CEBroker. ACMG is approved by the California Department of Health Services through the ASCLS P.A.C.E.®
CONTENT VALIDATION AND FAIR BALANCE
1. ACMG follows the ACCME policy on Content Validation for CME activities, which requires:
a) All recommendations involving clinical medicine must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients.
b) All scientific research referred to, reported or used in CME in support or justification of patient care recommendations must conform to the generally accepted standards of experimental design, data collection and analysis.
2. Activities that fall outside the definition of CME/CE; “Educational activities that serve to maintain, develop, or increase the knowledge, skills, and professional performance and relationships that a physician uses to provide services for patients, the public, or the profession” (source: ACCME and AMA) will not be certified for credit. CME activities that promote recommendations, treatment, or manners of practicing medicine or pharmacy that are not within the definition of CME/CE or, are known to have risks or dangers that outweigh the benefits or, are known to be ineffective in the treatment of patients.
3. Presentations and CME/CE activity materials must give a balanced view of therapeutic options; use of generic names will contribute to this impartiality. If the CME/CE educational materials or content includes trade names, where available, trade names from several companies must be used.
OFF-LABEL USES OF PRODUCTS
When an off-label use of a product, or an investigational use not yet approved for any purpose, is discussed during an educational activity, the accredited sponsor shall require the speaker to disclose that the product is not labeled for the use under discussion, or that the product is still investigational. Discussions of such uses shall focus on those uses that have been subject of objective investigation.
HIPAA COMPLIANCE BY FACULTY
The ACMG supports medical information privacy. While the ACMG is not a “covered entity” under HIPAA 1996 and therefore is not required to meet these standards, ACMG wishes to take reasonable steps to ensure that the presentation of individually identifiable health information at ACMG-sponsored events has been properly authorized. All presenters have completed a form indicating whether they intend to present any form of individually identifiable healthcare information. If so, they were asked either to attest that a HIPAA-compliant consent form is on file at their institution, or to send ACMG a copy of the ACMG HIPAA compliance form. This information is on record at the ACMG Administrative Office and will be made available upon request.
DISCLAIMER
ACMG educational programs are designed primarily as an educational tool for health care providers who wish to increase their understanding of the application of genomic technologies to patient care. The ACMG does not endorse, or recommend the use of this educational program to make patient diagnoses, particular by individuals not trained in medical genetics. Adherence to the information provided in these programs does not necessarily ensure a successful diagnostic outcome. The program should not be considered inclusive of all proper procedures and tests or exclusive of other procedures and tests that are reasonably directed at obtaining the same results. In determining the propriety of any specific procedure or test, a healthcare provider should apply his or her own professional judgment to the specific clinical circumstances presented by the individual patient or specimen.
Financial Disclosures
Disclosure Statement
The American College of Medical Genetics and Genomics has implemented a process where everyone who is in a position to influence and/or control the content of a continuing education activity must disclose all relevant financial relationships with any commercial interest within the past 12 months and any conflicts must be resolved prior to the activity. Participants of educational programs must be informed of an organizer’s and/or a presenter’s academic and professional affiliations and existence of any relevant financial relationship a presenter has with any proprietary entity producing heath care goods or services consumed by, or used on patients, with the exemption of non-profit or government organization and non-health care
related companies. The intent of this disclosure is not to prevent a speaker from making a presentation. This policy allows the participant to be fully knowledgeable in evaluating the information being presented. All disclosures have been reviewed by the COI sub-committee conflicts of interest are resolved. Disclosure includes any relevant relationship that may potentially bias the planning of the continuing education activity or may potentially bias one’s presentation or which, if known, could give the perception of bias.
Legend:
1. Major stockholder/ownership interest
2. Grant/Research Support (External)
3. Royalty (ies)/Honoraria
4. Consultant/consulting fees/other remuneration
5. Speakers bureau
6. Non-remunerative positions of influence such as officer, board member, trustee, or public spokesperson
7. Receipt of intellectual property
8. Consultant/Advisory Board
9. Other (Explain)
Financial Disclosures
Members of the ACMG Program Committee have the following disclosures:
Sarah Elsea, PhD, FACMG - Shire Genetic Therapies, 2
Akash Kumar, MD, PhD - MyOme, Inc, 1, 4
Anne Slavotinek, PhD, FACMG - UptoDate, 4, Wiley, Inc, Oxford, University Press, 3
The following members have nothing to disclose:
Speakers and Moderators Disclosures
Presenters and moderators have disclosed the following:
Berry, Susan – Sanofi, 3, 8
Biesecker, Leslie - ArQule, 2, Illumina, Inc, 6, Cold Spring Harbor Press, 3, Salary, Spouse/Legally recognized domestic partner; RTI International, 9
Burton, Barbara - Biomarin, Shire, Genzyme, Horizon, Alexion, 4
Brill, Joel - Ambu, AnX Robotica, Cernostics, Check Cap, Digma Medical, Diversatek, Dune Medical, Echosens, Endogastric Solutions, Erbe, Exact Sciences, Exalenz, Gala Therapeutics, Glaukos, Hello Heart, HyGIeaCare, Insightec, MaunaKea Technologies, Medtronic, Nuviera, Pacira, Penumbra, Proteus Digital Health, Reflexion, Senseonics, SonarMD, Stage Zero Life Sciences, Tabula Rosa Health Care, Tusker Medical, UCB Pharma, Vertos Medical, Wright Medical, 4
Carey, John - FDNA/Face2Gene, 8, John Wiley & Sons, Associate Editor American Journal of Medical Genetics, 4
Chung, Wendy - Regeneron Genetics Center, 8
Cunniff, Christopher - Biogen, 8, Eli Lilly and Company, 4
Dhar, Shweta - Acer Therapeutics, 8, PanGenomics, 1
Dubuc, Adrian - Lighthouse Lab Services and Thrive Genomics Rive Genomics, 4
Elsea, Sarah - Enzyvant, Millendo Therapeutics, 4, Shire, Inc. (Takeda), Vanda Pharmaceuticals, Rhythm Therapeutics, 2
Erlich, Yaniv - ArcBio, 8, LunaDNA, 4, DNA.Land, 1, Employee, MyHeritage, 9
Farrar, Michelle – Biogen, 4, 5, AveXis, 4, Roche 4
Freivogel, Mary - HCA/Sarah Cannon, 4, employee and stockholder, Invitae, 9
Gelb, Michael - PerkinElmer, Passage Bio, 4, Ultrageneyx, Takeda, Biomarin, CureGM1, 2
Gharavi, Ali - Astra Zeneca, 4, Renal Research Institute, 2
Gilllingham, Melanie - Ultragenyx Pharmaceutical, Reneo Pharmaceutial, 4
Gripp, Karen - FDNA, 8
Hagenkord, Jill - Former employee resigned June 2019, Color Genomics, 9
Hampel, Heather - Invitae, Genome, 23andMe, 8, Promega, 4, Myriad Genetics, 2
Harding, Cary - BioMarin Pharmaceutical Corp, Synlogic Inc, 4, StrideBio Inc, 2, Ultragenyx, Inc, 3
Hisama, Fuki - Spouse/Legally recognized domestic partner, Zogenix, 4
Hsiao, Susan - Bristol Myers Squibb, Loxo Oncology, 8, Bristol Myers Squibb, 2
Janicek, Mike - Astra Zeneca, Clovis, 5
Kishnani, Priya - Alexion Pharmaceuticals, 8, 2
Korf, Bruce - Genome Medical, 8, AstraZeneca, SprinWorks Therapeutics, 4
Kuhn, Robert - Regeneron Inc, 2, UCSC Genome Browser, 3
Kurian, Allison - Myriad Genetics 2
Lachmann, Robin –Sanofi Genzyme, Kyowa Kirin International, Biomarin, 4, Takeda, 3
Laney, Dawn - Sanofi-Genzyme, Takeda-Shire, Amicus Therapeutics, 4, ThinkGenetic Inc, 1
Li, Marilyn - Roche Sequencing Solutions, 8
Lyon, Elaine - Genoox, 4
Maisenbacher, Melissa - Employee, Natera, 9
Mardis, Elaine - Kiadis Pharmaceuticals NV, PACT Pharma LLC, Interpreta LLC, 8, Qiagen NV, 1, Board of Directors/Supervisory Board, Qiagen NV, 9
Might, Matthew - Q State Biosciences, 1
Monk, Bradley - Honorarium/Consultant, Abbvie, Advaxis, Agenus, Amgen, Aravive, Asymmetric Therapeutics, Boston Biomedical, ChemoCare, ChemoID, Circulogene, Conjupro, Easai, Geistlich, Genmab/Seattle Genetics, GOG Foundation, Immunogen, Immunomedics, Incyte, Laekna Health Care, Mateon (formally Oxigene), Merck, Mersana, Myriad, Nucana, Oncomed, Oncoquest, Oncosec, Perthera, Pfizer, Precision Oncology , Puma, Regeneron, Samumed, Takeda, VBL, Vigeo, Honorarium/Consultant/Speaker, AstraZeneca, Clovis, Janssen/Johnson & Johnson, Roche/Genentech, Tesaro/GSK, 9
Muenzer, Joseph - Sanofi Genzyme, Takeda (Shire), Bluebird Bio, 8, Takeda (Shire), Sangamo Therapeutics Inc, SOBI, 2
Nielsen, Sarah - Invitae, 1
Ortiz, Damara - Sanofi-Genzyme, 4
Palomaki, Glenn - Illumina, Ansh Labs, Roche, LabCorp, 4, PerkinElmer, 2
Phillips, Kathryn - Illumina, 4
Plotkin, Scott - AstraZeneca, 8, NFlection Therapeutics, NF2 Therapeutics, 1
Poduri, Annapurna - Tevard, 6, employee, Spouse/Legally recognized domestic partner, Sanofi Genzyme, 9
Rehder, Catherine - Illumina, 4
Robinson, Peter - NIH, European Commission, 2, Patent application for algorithm that will be discussed among various other topics, Jackson Laboratory, 9
Roy, Somak - Roche Sequencing Solutions, 8
Rush, Eric - Alexion Pharmaceuticals, Ultragenyx Pharmaceuticals, Biomarin Pharmaceuticals, 4, Alexion Pharmaceuticals, 2, Alexion Pharmaceuticals, Ultragenyx Pharmaceuticals, 5
Schiffmann, Raphael - Protalix Biotherapeutics, Amicus Therapeutics, 4D Molecular Therapeutics, 8, Idorsia, 2
Skotko, Brian - Gerson Lehrman Group, 4, LuMind IDSC Down Syndrome Foundation, 2, Woodbine House, 3
Slavin, Thomas - AstraZeneca, 3
Steiner, Robert - Acer Therapeutics, Censa Pharmaceuticals, E-Scape Bio, Alexion, 4, Alexion, 2, Acer Therapeutics, Censa Pharmaceuticals, 1, employee, PreventionGenetics, Security Health Plan, 9
Ferrar, Michelle - AveXis, Inc, Biogen, Roche, Biogen, 2
Sutton, V. Reid - PTC Therapeutics, PWN Health, 8, Mereo Biopharma, 2, salary support from Baylor Genetics Laboratory, Baylor Genetics, 9
Viskochil, David - Sanofi-Genzyme, Shire-Takeda, 8, Sanofi-Genzyme, 4, Soleno Therapeutics, Shire-Takeda, 2
The following moderators and presenters have nothing to disclose: